InterPAD - DETAILS

tolbutamide, 64-77-7, Orinase, Arkozal, Willbutamide, Butamide, Diabetamid, Ipoglicone, Glyconon, Rastinon, Tolbutamid, Aglicid, Artosin, Diaben, Tolumid, 1-Butyl-3-tosylurea, Diasulfon, Artozin, Butamid, Diabetol, Diabuton, Dirastan, Dolipol, Mobenol, Oterben, Pramidex, Tolbusal, Toluina, Toluvan, Tolylsulfonylbutylurea, 1-Butyl-3-(p-tolylsulfonyl)urea, Drabet, Orabet, Oralin, Orezan, Orinaz, Tolbutamidum, Sk-tolbutamide, N-(Butylcarbamoyl)-4-methylbenzenesulfonamide, N-n-Butyl-N'-tosylurea, Tolbutamida, 1-p-Toluenesulfonyl-3-butylurea, 1-Butyl-3-(p-methylphenylsulfonyl)urea, Arcosal, Beglucin, Butamidum, Diabesan, N-Butyl-N'-(p-tolylsulfonyl)urea, Tarasina, Tolbutone, Tolbet, N-Butyl-N'-p-toluenesulfonylurea, 3-(p-Tolyl-4-sulfonyl)-1-butylurea, N-(4-Methylphenylsulfonyl)-N'-butylurea, N-Butyl-N'-(4-methylphenylsulfonyl)urea, N-(4-Methylbenzenesulfonyl)-N'-butylurea, HLS 831, N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea, Orinase (TN), Tolumide, N-(p-Tolylsulfonyl)-N'-butylcarbamide, NCI-C01763, N-4-Methylbenzolsulfonyl-N-butylurea, Urea, 1-butyl-3-(p-tolylsulfonyl)-, D 860, Tolbutamidum [INN-Latin], 1-butyl-3-(4-methylphenyl)sulfonylurea, 1-Butyl-3-(4-methylphenylsulfonyl)urea, Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-, Tolbutamida [INN-Spanish], N-Butyl-N'-toluene-p-sulfonylurea, CCRIS 592, N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide, N-4-(Methylbenzolsulfonyl)-n-butylurea, HSDB 3393, N-(p-Methylbenzenesulfonyl)-N'-butylurea, UNII-982XCM1FOI, EINECS 200-594-3, 982XCM1FOI, MFCD00027169, NSC 23813, NSC-23813, U 2043, BRN 1984428, 3-butyl-1-(4-methylbenzenesulfonyl)urea, DTXSID8021359, CHEBI:27999, N-(Sulfonyl-p-methylbenzene)-N'-butylurea, 3-butyl-1-[(4-methylbenzene)sulfonyl]urea, Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-, NSC-87833, 1-BUTYL-3-(4-METHYLBENZENESULFONYL)UREA, CHEMBL782, N-((Butylamino)carbonyl)-4-methylbenzenesulfonamide, MLS000028399, DTXCID801359, Tolbutamide [USP:INN:BAN:JAN], 4-11-00-00396 (Beilstein Handbook Reference), CAS-64-77-7, toluran, NCGC00015999-10, SMR000058363, Tolbutamide form I^L^, Tolbutamidum (INN-Latin), Tolbutamida (INN-Spanish), TOLBUTAMIDE (MART.), TOLBUTAMIDE [MART.], TOLBUTAMIDE (USP-RS), TOLBUTAMIDE [USP-RS], TOLBUTAMIDE (EP MONOGRAPH), Tolbutamide (USP:INN:BAN:JAN), TOLBUTAMIDE [EP MONOGRAPH], TOLBUTAMIDE (USP MONOGRAPH), TOLBUTAMIDE [USP MONOGRAPH], SR-01000003059, tolbutamide IL, tolbutamide III, Prestwick_471, Spectrum_000447, Tolbutamide form I^H^, Opera_ID_112, TOLBUTAMIDE [MI], Prestwick0_000190, Prestwick1_000190, Prestwick2_000190, Prestwick3_000190, Spectrum2_001210, Spectrum3_000599, Spectrum4_000358, Spectrum5_001272, Lopac-T-0891, TOLBUTAMIDE [INN], TOLBUTAMIDE [JAN], N-n-Butyl-N''-tosylurea, TOLBUTAMIDE [HSDB], WLN: 4MVMSWR D1, T 0891, TOLBUTAMIDE [VANDF], NCIOpen2_009592, BIDD:PXR0179, CBiol_001920, Lopac0_001154, SCHEMBL15918, BSPBio_000119, BSPBio_001507, BSPBio_002078, KBioGR_000227, KBioGR_000795, KBioGR_002275, KBioSS_000227, KBioSS_000927, KBioSS_002276, TOLBUTAMIDE [WHO-DD], TOLBUTAMIDE [WHO-IP], MLS001148399, MLS002152944, DivK1c_000341, SPECTRUM1500581, SPBio_001000, SPBio_002040, BPBio1_000131, GTPL6848, Tolbutamide (JP17/USP/INN), Tolbutamide, analytical standard, HMS501B03, KBio1_000341, KBio2_000227, KBio2_000927, KBio2_002275, KBio2_002795, KBio2_003495, KBio2_004843, KBio2_005363, KBio2_006063, KBio2_007411, KBio3_000453, KBio3_000454, KBio3_001578, KBio3_002755, A10BB03, TOLBUTAMIDE [ORANGE BOOK], V04CA01, cMAP_000008, NINDS_000341, Bio1_000206, Bio1_000695, Bio1_001184, Bio2_000227, Bio2_000707, HMS1361L09, HMS1568F21, HMS1791L09, HMS1989L09, HMS2089C17, HMS2092M21, HMS2095F21, HMS2232H16, HMS3259A08, HMS3263H09, HMS3402L09, HMS3651N03, HMS3712F21, Pharmakon1600-01500581, BCP09192, HY-B0401, NSC23813, TOLBUTAMIDUM [WHO-IP LATIN], N-Butyl-N''-(p-tolylsulfonyl)urea, Tox21_110279, Tox21_201612, Tox21_302795, Tox21_501154, BDBM50027886, CCG-39141, NSC757354, NSC813220, s2443, 1-Butyl-3-(para-tolylsulfonyl)-urea, AKOS015894999, Tox21_110279_1, 1ST7197, DB01124, LP01154, NC00543, NSC-757354, NSC-813220, SDCCGSBI-0051121.P004, Tolbutamide 1.0 mg/ml in Acetonitrile, IDI1_000341, IDI1_033977, N-(n-Butyl)-N'-p-toluene-sulfonylurea, NCGC00015999-01, NCGC00015999-02, NCGC00015999-03, NCGC00015999-04, NCGC00015999-05, NCGC00015999-06, NCGC00015999-07, NCGC00015999-08, NCGC00015999-09, NCGC00015999-11, NCGC00015999-12, NCGC00015999-13, NCGC00015999-14, NCGC00015999-15, NCGC00015999-16, NCGC00015999-17, NCGC00015999-19, NCGC00015999-20, NCGC00015999-29, NCGC00022721-03, NCGC00022721-04, NCGC00022721-05, NCGC00022721-06, NCGC00022721-07, NCGC00022721-08, NCGC00022721-09, NCGC00022721-10, NCGC00256548-01, NCGC00259161-01, NCGC00261839-01, AC-12490, AS-14136, SY014891, N-(4-Methylphenylsulfonyl)-N''-butylurea, N-Butyl-N''-(4-methylphenylsulfonyl)urea, SBI-0051121.P003, DB-054728, AB00052110, EU-0101154, FT-0603265, N-(P-TOLYLSULFONYL)N'-BUTYLCARBAMIDE, NS00001371, SW196681-3, T3690, BIM-0051121.0001, C07148, D00380, D87667, EN300-124678, U-2043, AB00052110-16, AB00052110_17, AB00052110_18, N'-4-METHYLBENZENESULFONYL-N''-BUTYLUREA, Tolbutamide, VETRANAL(TM), analytical standard, A834879, Q414275, SR-01000003059-2, SR-01000003059-4, SR-01000003059-7, W-104820, BRD-K85119730-001-06-5, BRD-K85119730-001-17-2, N'-butyl-N-(p-tolylsulfonyl)carbamimidate;Tolbutamide, Z44591715, Tolbutamide, European Pharmacopoeia (EP) Reference Standard, 1-(([(Butylamino)carbonyl]amino)sulfonyl)-4-methylbenzene #, Tolbutamide, United States Pharmacopeia (USP) Reference Standard

Name	Tolbutamide
PubChem CID	5505
Molecular Weight	270.35g/mol
Synonyms	tolbutamide, 64-77-7, Orinase, Arkozal, Willbutamide, Butamide, Diabetamid, Ipoglicone, Glyconon, Rastinon, Tolbutamid, Aglicid, Artosin, Diaben, Tolumid, 1-Butyl-3-tosylurea, Diasulfon, Artozin, Butamid, Diabetol, Diabuton, Dirastan, Dolipol, Mobenol, Oterben, Pramidex, Tolbusal, Toluina, Toluvan, Tolylsulfonylbutylurea, 1-Butyl-3-(p-tolylsulfonyl)urea, Drabet, Orabet, Oralin, Orezan, Orinaz, Tolbutamidum, Sk-tolbutamide, N-(Butylcarbamoyl)-4-methylbenzenesulfonamide, N-n-Butyl-N'-tosylurea, Tolbutamida, 1-p-Toluenesulfonyl-3-butylurea, 1-Butyl-3-(p-methylphenylsulfonyl)urea, Arcosal, Beglucin, Butamidum, Diabesan, N-Butyl-N'-(p-tolylsulfonyl)urea, Tarasina, Tolbutone, Tolbet, N-Butyl-N'-p-toluenesulfonylurea, 3-(p-Tolyl-4-sulfonyl)-1-butylurea, N-(4-Methylphenylsulfonyl)-N'-butylurea, N-Butyl-N'-(4-methylphenylsulfonyl)urea, N-(4-Methylbenzenesulfonyl)-N'-butylurea, HLS 831, N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea, Orinase (TN), Tolumide, N-(p-Tolylsulfonyl)-N'-butylcarbamide, NCI-C01763, N-4-Methylbenzolsulfonyl-N-butylurea, Urea, 1-butyl-3-(p-tolylsulfonyl)-, D 860, Tolbutamidum [INN-Latin], 1-butyl-3-(4-methylphenyl)sulfonylurea, 1-Butyl-3-(4-methylphenylsulfonyl)urea, Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-, Tolbutamida [INN-Spanish], N-Butyl-N'-toluene-p-sulfonylurea, CCRIS 592, N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide, N-4-(Methylbenzolsulfonyl)-n-butylurea, HSDB 3393, N-(p-Methylbenzenesulfonyl)-N'-butylurea, UNII-982XCM1FOI, EINECS 200-594-3, 982XCM1FOI, MFCD00027169, NSC 23813, NSC-23813, U 2043, BRN 1984428, 3-butyl-1-(4-methylbenzenesulfonyl)urea, DTXSID8021359, CHEBI:27999, N-(Sulfonyl-p-methylbenzene)-N'-butylurea, 3-butyl-1-[(4-methylbenzene)sulfonyl]urea, Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-, NSC-87833, 1-BUTYL-3-(4-METHYLBENZENESULFONYL)UREA, CHEMBL782, N-((Butylamino)carbonyl)-4-methylbenzenesulfonamide, MLS000028399, DTXCID801359, Tolbutamide [USP:INN:BAN:JAN], 4-11-00-00396 (Beilstein Handbook Reference), CAS-64-77-7, toluran, NCGC00015999-10, SMR000058363, Tolbutamide form I^L^, Tolbutamidum (INN-Latin), Tolbutamida (INN-Spanish), TOLBUTAMIDE (MART.), TOLBUTAMIDE [MART.], TOLBUTAMIDE (USP-RS), TOLBUTAMIDE [USP-RS], TOLBUTAMIDE (EP MONOGRAPH), Tolbutamide (USP:INN:BAN:JAN), TOLBUTAMIDE [EP MONOGRAPH], TOLBUTAMIDE (USP MONOGRAPH), TOLBUTAMIDE [USP MONOGRAPH], SR-01000003059, tolbutamide IL, tolbutamide III, Prestwick_471, Spectrum_000447, Tolbutamide form I^H^, Opera_ID_112, TOLBUTAMIDE [MI], Prestwick0_000190, Prestwick1_000190, Prestwick2_000190, Prestwick3_000190, Spectrum2_001210, Spectrum3_000599, Spectrum4_000358, Spectrum5_001272, Lopac-T-0891, TOLBUTAMIDE [INN], TOLBUTAMIDE [JAN], N-n-Butyl-N''-tosylurea, TOLBUTAMIDE [HSDB], WLN: 4MVMSWR D1, T 0891, TOLBUTAMIDE [VANDF], NCIOpen2_009592, BIDD:PXR0179, CBiol_001920, Lopac0_001154, SCHEMBL15918, BSPBio_000119, BSPBio_001507, BSPBio_002078, KBioGR_000227, KBioGR_000795, KBioGR_002275, KBioSS_000227, KBioSS_000927, KBioSS_002276, TOLBUTAMIDE [WHO-DD], TOLBUTAMIDE [WHO-IP], MLS001148399, MLS002152944, DivK1c_000341, SPECTRUM1500581, SPBio_001000, SPBio_002040, BPBio1_000131, GTPL6848, Tolbutamide (JP17/USP/INN), Tolbutamide, analytical standard, HMS501B03, KBio1_000341, KBio2_000227, KBio2_000927, KBio2_002275, KBio2_002795, KBio2_003495, KBio2_004843, KBio2_005363, KBio2_006063, KBio2_007411, KBio3_000453, KBio3_000454, KBio3_001578, KBio3_002755, A10BB03, TOLBUTAMIDE [ORANGE BOOK], V04CA01, cMAP_000008, NINDS_000341, Bio1_000206, Bio1_000695, Bio1_001184, Bio2_000227, Bio2_000707, HMS1361L09, HMS1568F21, HMS1791L09, HMS1989L09, HMS2089C17, HMS2092M21, HMS2095F21, HMS2232H16, HMS3259A08, HMS3263H09, HMS3402L09, HMS3651N03, HMS3712F21, Pharmakon1600-01500581, BCP09192, HY-B0401, NSC23813, TOLBUTAMIDUM [WHO-IP LATIN], N-Butyl-N''-(p-tolylsulfonyl)urea, Tox21_110279, Tox21_201612, Tox21_302795, Tox21_501154, BDBM50027886, CCG-39141, NSC757354, NSC813220, s2443, 1-Butyl-3-(para-tolylsulfonyl)-urea, AKOS015894999, Tox21_110279_1, 1ST7197, DB01124, LP01154, NC00543, NSC-757354, NSC-813220, SDCCGSBI-0051121.P004, Tolbutamide 1.0 mg/ml in Acetonitrile, IDI1_000341, IDI1_033977, N-(n-Butyl)-N'-p-toluene-sulfonylurea, NCGC00015999-01, NCGC00015999-02, NCGC00015999-03, NCGC00015999-04, NCGC00015999-05, NCGC00015999-06, NCGC00015999-07, NCGC00015999-08, NCGC00015999-09, NCGC00015999-11, NCGC00015999-12, NCGC00015999-13, NCGC00015999-14, NCGC00015999-15, NCGC00015999-16, NCGC00015999-17, NCGC00015999-19, NCGC00015999-20, NCGC00015999-29, NCGC00022721-03, NCGC00022721-04, NCGC00022721-05, NCGC00022721-06, NCGC00022721-07, NCGC00022721-08, NCGC00022721-09, NCGC00022721-10, NCGC00256548-01, NCGC00259161-01, NCGC00261839-01, AC-12490, AS-14136, SY014891, N-(4-Methylphenylsulfonyl)-N''-butylurea, N-Butyl-N''-(4-methylphenylsulfonyl)urea, SBI-0051121.P003, DB-054728, AB00052110, EU-0101154, FT-0603265, N-(P-TOLYLSULFONYL)N'-BUTYLCARBAMIDE, NS00001371, SW196681-3, T3690, BIM-0051121.0001, C07148, D00380, D87667, EN300-124678, U-2043, AB00052110-16, AB00052110_17, AB00052110_18, N'-4-METHYLBENZENESULFONYL-N''-BUTYLUREA, Tolbutamide, VETRANAL(TM), analytical standard, A834879, Q414275, SR-01000003059-2, SR-01000003059-4, SR-01000003059-7, W-104820, BRD-K85119730-001-06-5, BRD-K85119730-001-17-2, N'-butyl-N-(p-tolylsulfonyl)carbamimidate;Tolbutamide, Z44591715, Tolbutamide, European Pharmacopoeia (EP) Reference Standard, 1-(([(Butylamino)carbonyl]amino)sulfonyl)-4-methylbenzene #, Tolbutamide, United States Pharmacopeia (USP) Reference Standard
Drug Type	Small molecule
Formula	C₁₂H₁₈N₂O₃S
SMILES	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
InChI	1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
InChIKey	JLRGJRBPOGGCBT-UHFFFAOYSA-N
CAS Number	64-77-7
ChEMBL ID	CHEMBL782
ChEBI ID	CHEBI:27999
TTD ID	D06OIV
Drug Bank ID	DB01124
KEGG ID	C07148
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Tolbutamide
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.